Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.56 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140823 | 0.91 | MAPT (0.58) | KCNQ3KCNQ2FASNCSF1RDAPK1 | |
| SCHEMBL1140406 | 0.91 | MAPT (0.62) | KCNQ3KCNQ2CSF1RDAPK1RAB9A | |
| SCHEMBL1140370 | 0.90 | FASN (0.60) | KCNQ3KCNQ2FASNCSF1RDAPK1 | |
| SCHEMBL16986681 | 0.87 | CSF1R (0.46) | KCNQ3KCNQ2FASNCSF1RDAPK1 | |
| SCHEMBL1140704 | 0.87 | KCNQ3 (0.56) | KCNQ3KCNQ2RAB9AMAPTLMNA | |
| SCHEMBL1140434 | 0.85 | MAPT (0.47) | KCNQ3KCNQ2FASNCSF1RDAPK1 | |
| SCHEMBL6340639 | 0.85 | MAPT (0.47) | KCNQ3KCNQ2FASNCSF1RDAPK1 | |
| SCHEMBL1140677 | 0.82 | KCNQ3 (0.57) | KCNQ3KCNQ2FASNRAB9AMAPT | |
| SCHEMBL1140401 | 0.82 | KCNQ3 (0.52) | KCNQ3KCNQ2FASNRAB9AMAPT | |
| SCHEMBL1140636 | 0.81 | MAPT (0.59) | KCNQ3KCNQ2FASNCSF1RDAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | claimed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | disclosed |
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| EP-2346499-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011062939-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110039850-A1 | Leukemia Treatment | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2011-02-17 | — | — | US | disclosed |
| WO-2011019798-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | KCNQ3 2396/4885KCNQ2 2508/4885FASN 628/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | KCNQ3 3080/4885KCNQ2 2963/4885FASN 3081/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | KCNQ3 4000/4885KCNQ2 3814/4885FASN 2368/4885 |
| US-20110039850-A1 | Leukemia Treatment | ABL1, MCL1, BCR | KCNQ3 4560/4885KCNQ2 4455/4885FASN 4435/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | KCNQ3 4000/4885KCNQ2 3814/4885FASN 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.